ALK-Abelló A/S (Nasdaq Copenhagen: ALK B, ticker reference 0OIR), the Denmark-headquartered global specialty pharmaceutical company focused on allergy, has confirmed that president and chief executive Peter Halling will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, 18 November 2026 at 10.00 AM GMT. The event runs from 16 to 19 November 2026, and company representatives will also be available for one-on-one meetings with attendees. Investors and analysts tracking ALK's strategic direction may note that the session will be webcast live and subsequently archived on ALK's investor relations website.

Key Points

  • ALK-Abelló A/S (Nasdaq Copenhagen: ALK B / 0OIR)
  • CEO Peter Halling is scheduled for a fireside chat at the Jefferies Global Healthcare Conference in London on 18 November 2026 at 10.00 AM GMT / 11.00 AM CET
  • The conference runs 16–19 November 2026; a live webcast and post-event recording will be accessible via ALK's investor relations site
  • Investors should watch for any commentary on ALK's allergy portfolio and pipeline that may emerge from the fireside chat or associated meetings

Peter Halling Scheduled for Fireside Chat on 18 November at Jefferies London Conference

According to the company's announcement, ALK president and CEO Peter Halling will take part in a fireside chat format session on Wednesday, 18 November 2026, beginning at 10.00 AM GMT, as part of the broader Jefferies Global Healthcare Conference. The four-day conference is being held in London between 16 and 19 November 2026. The announcement states that company representatives will be available for investor meetings at the conference, indicating that institutional engagement is a key objective of ALK's participation alongside the public presentation element.

Live Webcast and Archived Recording to Be Available on ALK's Investor Relations Site

ALK has confirmed that a live webcast of the fireside chat will be accessible through a dedicated link and hosted on the company's investor relations webpage. Following the event, a recording will also be archived on the same site, allowing investors who are unable to attend in person or view the live stream to access the content at a later date. This approach reflects standard investor communications practice for listed pharmaceutical companies and ensures broad accessibility for shareholders and analysts monitoring ALK's strategic messaging.

ALK's Global Allergy Pharmaceutical Portfolio Spans Diagnosis, Treatment and Anaphylaxis

ALK describes itself as a global specialty pharmaceutical company focused exclusively on allergy. The company's activities, as stated in the announcement, cover the full value chain from developing and sourcing through to producing and marketing products for diagnosing and treating respiratory allergies and severe allergic reactions, including anaphylaxis, in both children and adults. Headquartered in Denmark, ALK employs approximately 2,800 people worldwide. The company is listed on Nasdaq Copenhagen under the ticker ALK B, with investor relations contact Per Plotnikof reachable at +45 4574 7527.